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Abstract
Despite growing appreciations of the importance of long non-coding RNA (lncRNA) in normal
physiology and disease, our knowledge of cancer-related lncRNA remains limited. By repurposing
microarray probes, we constructed the expression profile of 10,207 lncRNA genes in
approximately 1,300 tumors over four different cancer types. Through integrative analysis of the
lncRNA expression profiles with clinical outcome and somatic copy number alteration (SCNA),
we identified lncRNA that are associated with cancer subtypes and clinical prognosis, and
predicted those that are potential drivers of cancer progression. We validated our predictions by
experimentally confirming prostate cancer cell growth dependence on two novel lncRNA. Our
analysis provided a resource of clinically relevant lncRNA for development of lncRNA
biomarkers and identification of lncRNA therapeutic targets. It also demonstrated the power of
integrating publically available genomic datasets and clinical information for discovering disease
associated lncRNA.
Systematic efforts to catalogue long non-coding RNA (lncRNA) using traditional cDNA
Sanger sequencing1, histone mark ChIP-seq2, 3, or RNA-seq4, 5 data revealed that the human
genome encodes over 10,000 lncRNA with little coding capacity. Growing evidences
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suggest that in cancer lncRNA, like protein-coding genes (PCGs), may mediate oncogenic
or tumor suppressing effects and promise to be a new class of cancer therapeutic targets6.
While a handful of lncRNA have been functionally characterized, little is known about the
function of most lncRNA in normal physiology or disease7. LncRNA may also serve as
cancer diagnostic or prognostic biomarkers that are independent of PCG. A well-known
example of a potential cancer diagnostic biomarker is PCA3, a prostate-specific lncRNA
gene that is significantly overexpressed in prostate cancer. Noninvasive monitoring of
urinary PCA3 transcript level is currently being developed for diagnostics in the clinic8.
As lncRNA do not encode proteins, their functions are closely associated with their
transcript abundance. RNA-seq is a comprehensive way to profile lncRNA expression.
However, due to the higher cost associated with the adoption of this technique, publically
available RNA-seq datasets of tumors are relatively limited compared with array-based
expression profiles. In addition, RNA-seq datasets with low sequencing coverage or small
sample numbers have only limited statistical power to discover clinically relevant lncRNA.
In contrast, there are a large number of datasets that contain array-based gene expression
profiles across hundreds of tumor samples. These array-based expression profiles are often
accompanied with matched clinical annotation and/or somatic genomic alteration profiles
such as somatic copy number alteration (SCNA). Although lncRNA are not the intended
targets of measurement in the original array design, microarray probes can be re-annotated
for interrogating lncRNA expression9-14. Compared with RNA-seq data of low sequencing
coverage, array-based expression data may have lower technical variation and better
detection sensitivity for low-abundance transcripts15, 16, a prominent feature of lncRNA5.
Moreover, array-based expression data contain strand information and allow for
interrogating expression of anti-sense single-exon lncRNA, whereas most of current RNA-
seq data in clinical applications do not have strand information and thus are unable to
accurately quantify the expression of this class of lncRNA17.
To repurpose the publically available array-based data to interrogate lncRNA expression in
tumor samples, we developed a computational pipeline to re-annotate the probes that are
uniquely mapped to lncRNA using the latest annotations of lncRNA and PCG. We further
performed integrative genomic analyses of lncRNA expression profiles, clinical information
and SCNA profiles of tumors in four different cancer types including 150 tumor samples of
prostate cancer from the MSKCC Prostate Oncogenome Project18 and 451 tumor samples of
glioblastoma multiforme (GBM), 585 tumor samples of ovarian cancer (OvCa) and 113
tumor samples of lung squamous cell carcinoma (Lung SCC) from the Cancer Genome
Atlas Research Network (TCGA) project19. We identified lncRNA that are significantly
associated with cancer subtypes or cancer prognosis and predicted those that may play tumor
promoting or suppressing function.
Results
Repurposing microarray data for probing lncRNA expression
Among the different gene expression microarray platforms, we focused on reannotating the
probes from Affymetrix microarrays. These arrays not only have many more short probes
that are likely to map to lncRNA genes, but have been the most widely used platforms for
gene expression profiling of patient tumor samples. We designed a computational pipeline to
re-annotate the probes from five Affymetrix array types (Methods, Fig. 1a), and kept
annotated lncRNA and PCG transcripts with at least 4 probes uniquely mapped to them.
Among the five Affymetrix array types, Affymetrix Human Exon 1.0 ST array has the most
comprehensive coverage of the annotated human lncRNA (Supplementary Table 1). In total,
10,207 lncRNA genes have at least 4 probes covering their annotated exons (Fig. 1a), which
constitute approximately 64% of all 15,857 lncRNA genes (with over 60% coverage in each
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category20 of lncRNA genes) collected in this study (Methods, Fig. 1b,c, Supplementary
Table 2). We focused our studies on the Affymetrix exon-array-expression profiles because
of its most comprehensive coverage of lncRNA.
We used a model-based method21 (Methods) to derive the gene expression index of all the
PCGs and lncRNA on exon arrays. To gauge the reliability of our approach, we examined
the correlation of both lncRNA and PCG expression between exon array and RNA-seq data
that were generated from two different laboratories using the same prostate cancer cell line
LNCaP18, 22. We found that both PCG (r=0.70, p<2.2x10−16) and lncRNA (r=0.29,
p<2.2x10−16) showed significant concordance of expression between exon array and RNA-
seq data (Supplementary Fig. 1a,b). This observation is consistent with the previous finding
that the correlation between microarrays and RNA-seq is lower in lowly-expressed genes23,
as lncRNA generally are expressed at lower levels than PCG5. As the level of probe
coverage could also influence the accuracy of lncRNA expression derived from microarray,
we further investigated how the correlation of expression between exon array and RNA-seq
changes at different probe-coverage by examining those PCGs that have similar expression
level to that of lncRNA (Supplementary Fig. 1c). We found that the correlation between
exon-array and RNA-seq based expression showed a moderate increase when all probes
(0.28) were used compared with when only 4 probes (0.20) were used (Supplementary Fig.
1c). The correlations were similar for PCGs (0.28) and lncRNA (0.29) when the expression
level was controlled for. These results suggest that although the probe coverage may
influence the array-based lncRNA expression estimation, the dominant factor that governs
the observed difference in correlation between array and RNA-seq for PCGs versus lncRNA
is their expression level. A recent study, in which a 60-mer custom oligonucleotide array
was designed to investigate lncRNA expression, showed that the correlation of lncRNA
expression between the custom array and RNA-seq data was between 0.24 and 0.3120.
Therefore, although the concordance between exon arrays and RNA-seq is lower for
lncRNA than for PCG expression, it may represent the typical performance when comparing
lncRNA expression between an array-based platform and RNA-seq.
LncRNA associated with cancer status, subtype and prognosis
To validate the utility of exon array data in combination with clinical annotation to identify
cancer-related lncRNA, we examined the expression pattern of thirteen literature-curated
cancer-related lncRNA6 that have corresponding exon array probes in a prostate cancer
dataset18. This dataset consists of 29 normal prostate samples, 131 primary and 19
metastatic prostate tumor samples with exon array data18 (Fig. 2a). Interestingly, nine out of
these thirteen known cancer-related lncRNA showed significantly differential expression
between tumor and normal prostate samples (Mann-Whitney U test, p<0.05). Three out of
these nine lncRNA were directly related to prostate cancer, including one known prostate
cancer diagnostic biomarker PCA38, and two, PCAT-122 and PCGEM124, that have been
functionally implicated in prostate cancer progression. GAS5, a tumor-suppressive lncRNA
known to be down regulated in breast cancer25, showed increased expression in prostate
cancer (Table 1), suggesting complex and context-dependent functions of lncRNA in
different cancer types. Interestingly, several lncRNA such as NEAT126, DANCR27,
HOTTIP28, PRINS29, and EGOT30 that have established functions in forming nuclear
speckles26, in development27 or in autoimmune disease29, but were not previously known to
be related to cancer, showed differential expression between tumor and normal prostate
samples (Table 1), suggesting their potential function in prostate cancer.
We next sought to identify lncRNA that showed significant expression difference between
tumors and normal prostate tissues, and found 109 up- and 104 down-regulated lncRNA
(Mann-Whitney U test, false discovery rate (FDR) <0.05, fold-change≥1.5), respectively
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(Fig. 2a). Notably, among the lncRNA with sufficient exon-array probe coverage, we re-
discovered 7 out of 8 lncRNA which were reported to show higher expression in prostate
cancer from an independent study based on RNA-seq data22. Furthermore, we identified an
additional 102 lncRNA genes which were up-regulated in prostate cancer, but were missed
by the other study22, suggesting that arrays and RNA-seq may be complementary methods
to identify clinically relevant lncRNA. When a lncRNA acts in cis and influences the
expression of its neighboring PCG or a lncRNA and its neighboring PCG are under the same
cis-regulation, they can show coordinated expressions. We compared the distribution of the
correlation between lncRNA and its neighboring PCG from different lncRNA classes
(Supplementary Table 2). Interestingly, antisense genic lncRNAs are slightly better
correlated with their sense PCG than intergenic lncRNA (pvalue < 10−10) (Supplementary
Fig. 2a,b), suggesting a more co-coordinated expression between sense PCG and anti-sense
lncRNA gene.
Cancer is a clinically heterogeneous disease and individual cancer types can be further
divided into molecular subtypes, each with its specific biological and clinical behavior.
Previous studies established 4 subtypes of GBM (proneural, neural, classical and
mesenchymal subtype)19, 4 subtypes of OvCa (immunoreactive, proliferative, mesenchymal
and differentiated subtype)31, 4 subtypes of Lung SCC (basal, classical, primitive and
secretory subtype)32 based on the expression profile of PCG, and 6 subtypes of prostate
cancer based on the SCNA profiles18.
LncRNA with subtype-specific expression may have important function in individual
molecular subtypes. We compared the lncRNA expression across different subtypes
(Methods) and identified hundreds of lncRNA showing subtype-specific expression patterns
in GBM, OvCa and Lung SCC (Fig. 2b-e). The same approach did not yield any lncRNA
that show significant subtype-specific expression in prostate cancer, which was a
reminiscence of the lack of robust PCG-expression-based subtype of prostate cancer18. In
addition, 628 lncRNA showed subtype-specific expression in more than one cancer type
(Fig. 2b) and some of them have been functionally implicated in other physiological or
pathological processes. For example, MIAT, a lncRNA which showed specific expression in
mesenchymal subtype of OvCa and in proneural subtype of GBM, is known to confer risk of
myocardial infarction33 and regulate retinal cell fate specification34. Another example is
RMST, a lncRNA known to be differentially expressed between rhabdomyosarcoma
subtypes35, also exhibited subtype-specific expression patterns in GBM, OvCa and Lung
SCC.
A previous study of HOTAIR36, 37 showed that patients with higher HOTAIR expression
had poorer prognosis in colorectal cancer38. To identify the lncRNA, which are associated
with clinical outcome in prostate cancer, GBM, OvCa and Lung SCC, we performed
multivariate Cox regression analysis to evaluate the significance of correlation between
individual lncRNA expression and overall- and progression-free survival in the presence of
other confounding factors such as ethnicity, age and gender (Methods). We identified
approximately 100 lncRNA each in prostate cancer, GBM, OvCa and Lung SCC, whose
expression was significantly correlated with overall or progression-free survival (p< 0.01,
Supplementary Table 3). Interestingly, nine lncRNA showed consistent positive or negative
correlation between their expression and overall or progression-free survival in different
cancer types, suggesting their potential as more general prognostic biomarkers. The lncRNA
gene, with the Ensembl ID ENSG00000261582 is an example of a lncRNA that showed
negative correlation between its expression and overall survival in both Lung SCC and
OvCa (Fig. 3a). This lncRNA also showed subtype-specific expression in OvCa, but not in
Lung SCC. Additionally, five lncRNA showed significant and consistent positive or
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negative correlation between both overall and progression-free survival in OvCa and one
such example (Ensembl ID ENSG00000225128) was shown (Fig. 3b).
Predicting lncRNA that are potential cancer drivers
An important form of somatic genetic alteration in cancer is SCNA, in which a genomic
region is either amplified or deleted. Some of the genes within amplified (or deleted) regions
show increased (or decreased) expression level, leading to altered activity in cancer cells.
Studies suggest that the genes playing causal roles in oncogenesis are often located in the
SCNA that are altered frequently across tumors39, 40. To reveal the lncRNA that may play
tumor promoting or suppressing function, we identified hundreds of lncRNA that map to
regions of recurrent SCNA across tumors (Methods) for prostate cancer, GBM, OvCa and
Lung SCC (Fig. 3c). Some of these lncRNA also showed significant correlation between
overall or progression-free survival (Supplementary Table 4). In addition, we identified
lncRNA that were consistently located in the regions of SCNA across different cancers (Fig.
3c) and found a significant overlap of the lncRNA genes that are in the SCNA gain or loss
regions between some of cancer types (Supplementary Table 5).
Among the many genes located within regions of SCNA, only a fraction of them are likely
to be drivers of cancer. To further distinguish driver from passenger lncRNA in the regions
of SCNA, we integrated SCNA and expression profiles of lncRNA in tumors. We reasoned
that driver lncRNA with SCNAs should result in corresponding gene expression
changes40, 41, as only those SCNAs that cause the change of transcript abundance could
possibly alter lncRNA activity. Therefore, we selected lncRNA whose SCNAs showed
positive correlation with expression level change as the candidate drivers (Methods,
Supplementary Table 3) for prostate cancer, GBM, OvCa and Lung SCC.
Experimental validation of two novel lncRNA
As it is prohibitive to validate all the candidate driver lncRNA in four cancer types, we
focused our experimental validation on candidate lncRNA that may have tumor promoting
function in prostate cancer (i.e. those in recurrent SCNA (gain) regions, which showed
positive correlation between their SCNAs and expression level). Among all the candidate
driver lncRNA that showed increasing expression from normal to primary to metastatic
prostate cancer, we chose the two that showed most significant expression difference
between tumor and normal prostate tissue (i.e. the smallest p- value from Mann-Whitney U
test) for experimental validation. We named these two lncRNA as Prostate Cancer
Associated Non-coding RNA 1 and 2, abbreviated as PCAN-R1 (Ensembl ID
ENSG00000228288) and PCAN-R2 (Ensembl ID ENSG00000231806), respectively. Both
lncRNA showed positive correlation between gene expression and SCNA (Fig. 4a and
Supplementary Fig. 3a). The criteria of increasing expression from normal to primary to
metastatic prostate cancer aimed to uncover lncRNA that may be important therapeutic
targets for both primary and metastatic cancers (Fig. 4b). Coding potential analysis
confirmed the non-coding nature of these two LncRNA (Methods). We chose the prostate
cancer cell line LNCaP for experimental validation in which both lncRNA have moderate or
higher expression level compared with other prostate cancer or non-prostate cancer cell lines
(Supplementary Fig. 3b,c). Using 5′ and 3′ RACE, we found that for PCAN-R1, while one
isoform PCAN-R1-A was almost identical to the Ensembl annotated transcript
ENST00000425295 (Fig. 4c, Supplementary Fig. 4a), the other isoform PCAN-R1-B was a
spliced variant of PCAN-R1-A with an intron retention (Fig. 4c). Interestingly, for PCAN-
R2, the major isoform had an extra exon in the 5′ end, and the remaining two exons also had
different lengths from the Ensembl annotation (Fig. 4c, Supplementary Fig. 4b). The new 5′
exon of PCAN-R2 was more consistent with the profile of H3K4me3, a histone mark of
active promoter and the profile of DNase I hypersensitive regions (i.e. the regions with an
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open chromatin state) in LNCaP cells. We further confirmed the transcript structure of
PCAN-R1 and PCAN-R2 by Northern blot (Fig. 5a, Methods).
Based on the determined lncRNA transcript structures, we designed siRNAs that targeted
the common exon of each lncRNA gene. Notably, knockdown of either PCAN-R1 or
PCAN-R2 using two different siRNA (Fig. 5b) resulted in substantial decrease in both cell
growth (Fig. 5c) and soft-agar colony formation in the androgen-dependent prostate cancer
cell line LNCaP (Fig. 5d). We further confirmed this growth inhibition upon lncRNA
knockdown in the androgen-independent prostate cancer cell line LNCaP-abl
(Supplementary Fig. 5a,b). To rule out the possibility that the observed phenotypes were
from siRNA off-target effect on PCG expression, we searched the homologous sequences of
the designed siRNA sequences in all protein-coding transcripts. We found no hit with the
perfect match or one mismatch, and only found five transcripts from five genes for all the
siRNAs when two mismatches were allowed. Among these, two PCGs MYSM1 (potentially
targeted by siR1-1) and ADAMTS17 (potentially targeted by siR2-2) showed elevated
expression in prostate tumors than in normal samples, which resembled PCAN-R1 and
PCAN-R2 in terms of expression pattern and accordingly indicated their potentials of
functionality. The expression of these two genes were unaffected upon corresponding
siRNA treatment, suggesting that the observed cellular phenotype upon siRNA knockdown
of the selected lncRNA was unlikely to be from off-target effect on PCGs (Supplementary
Fig. 5c,d).
As a lncRNA may act in cis and influence the expression of its neighboring PCG, we
investigated whether the expression of the neighboring PCG was regulated by PCAN-R1 or
PCAN-R2. The siRNA knockdown of PCAN-R1 or PCAN-R2 had no effect on the
expression of their neighboring PCG KDM5B and FBP2 (Supplementary Fig. 5c,d)
respectively, suggesting that the functional mechanism of PCAN-R1/-R2 are not directly
through their neighboring PCG. Interestingly, in normal tissues, PCAN-R1 and its
neighboring PCG KDM5B showed the highest expression in testis (Supplementary Fig.
5e,f). In contrast, while PCAN-R2 showed a similar expression across different tissues, its
neighboring PCG FBP2 exhibited muscle-specific expression pattern (Supplementary Fig.
5e,f), suggesting that the expression of PCAN-R2 and FBP2 may be differently regulated.
Discussion
Our analyses demonstrated that repurposing microarray probes to construct lncRNA
expression profile in patient sample is a cost-effective approach, given the large number of
such datasets available in public repositories. The constructed gene expression profiles of
both lncRNA and PCGs from our analyses is a valuable resource for understanding the
similarity and difference of transcriptional (e.g. antisense RNA42) regulation of PCGs by
lncRNA across different cancer types. In combination of matched SCNA profile and clinical
information, these gene expression profiles also allow for inferring network models43, 44 that
will help to advance the understanding of lncRNA function in cancer etiology.
More importantly, the experimental validation of two lncRNA without previous implication
in cancer suggested the effectiveness of our integrative analyses in finding functionally
important lncRNA in cancer. Our analyses predicted about 80 to 300 candidate driver
lncRNA that may have tumor promoting function in each of four cancers, respectively. An
intersection of such list of candidate driver lncRNA with the list of lncRNA generated from
orthogonal functional genomic datasets such as ribonucleoprotein immunoprecipitation
(RIP) followed by sequencing (RIP-seq)45 data (a genomic technique for identifying
lncRNA physically associated with the protein of interest), would greatly help to prioritize
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their functional valuation in different biological context including epigenetic regulation and
facilitate the discovery of lncRNA therapeutic targets.
In current study, we only utilized SCNA and expression data in combination with clinical
information for our integrative analysis. It is conceivable that other types of genomic data
such as SNP array46 and genome sequencing data47 can be further integrated to reveal the
multifaceted relationship between mutation spectrum and expression of lncRNA, disease
status, and clinical outcome.
In summary, our study represents a proof-of-principle study for identifying clinically
relevant lncRNA through integrative analyses of orthogonal genomic datasets and clinical
information. It opens new avenues for leveraging publicly available genomic data to study
the functions and mechanisms of lncRNA in human diseases.
Methods
Repurposing data from Affymetrix Human Exon 1.0 ST array and Affymetrix 3′ IVT arrays
to interrogate lncRNA expression
We collected long non-coding RNA (lncRNA) annotation from two sources: the catalogue
of lncRNA from Ensembl database48 (Homo sapiens GRCh37, release 67) and the catalog of
lncRNA generated based on transcriptome assembly from RNA-seq data5. For those
lncRNA transcripts that have overlap on the same strand between these two sources, we only
kept the Ensembl annotation (Fig. 1a) to avoid redundancy. This resulted in a total of 15,857
lncRNA genes. We re-annotated probe sets of Human Exon array for lncRNA by mapping
all probes to the human genome (hg19) using SeqMap49. We kept those probes that were
uniquely mapped to the genome with no mismatch. We then removed all probes that were
mapped to protein-coding transcripts (183,252) and pseudogene transcripts (15,789) based
on the annotations from Ensembl48 (http://www.ensembl.org) and UCSC50 (http://
www.genome.ucsc.edu) database. By matching the rest probes to lncRNA sequences, we
obtained 202,449 probes and 10,207 corresponding lncRNA genes with at least 4 probes.
The same strategy was applied to generate the probes that correspond to lncRNA transcripts
for other 3′ IVT Affymetrix array platforms. The raw intensity of exon array probes was
corrected using a probe-sequence-specific background model and the expression level of a
lncRNA gene was calculated by summarizing the background-corrected intensity of all
probes corresponding to this gene21. The lncRNA expression was quantile-normalized
across different biological samples. The gene expression calculation was implemented using
Jetta51. When the batch information is available, Combat52, an empirical Bayes method was
used to remove potential batch effect.
LncRNA classification
The classification scheme was adopted from Derrien et al20. The lncRNA were categorized
into intergenic and genic ones. The neighboring protein-coding genes of lncRNA were
selected based on (1) The nearest distance of the lncRNA or (2) the longest overlapped
regions. The intergenic lncRNA were sub-classified as “same strand”, “convergent” and
“divergent” according to their relative orientation with the neighboring protein-coding
genes. The genic lncRNA were classified as being exonic, intronic and overlapping and
sense and antisense according to their relation with neighboring protein-coding genes. The
classification of all lncRNA genes that have at least 4 exon-array probes was listed as a
supplementary dataset (supplementary-file1.xlsx)
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Comparative analysis of exon array and RNA-seq data
We obtained RNA-seq22 and exon array18 data of LNCaP cell line from two different
studies18, 22. The RNA-seq-based gene expression was calculated using
Cufflinks1.0.253(default parameter and -G option) and the exon-array-based gene expression
was calculated using the same procedure as was described in the last section. The Pearson
correlation coefficient was used to quantify the strength of the association between exon-
array-based and RNA-seq-based expression.
Exon array data, clinical annotation and SCNA data of different cancers
For prostate cancer, we obtained exon array data, clinical annotation and SCNA data
generated by the MSKCC Prostate Oncogenome Project18 from Gene expression Omnibus
(GEO) (GSE21034). This dataset included 29 normal adjacent, 131 primary and 19
metastatic tissue specimens as well as 4 prostate cell lines with exon-array data. The exon
array data, clinical annotation and SCNA data of 451 GBM19, 585 OvCa31 and 113 Lung
SCC32 primary tumors were downloaded from The Cancer Genome Atlas (TCGA, https://
tcga-data.nci.nih.gov). We further obtained exon array data of 11 human normal tissues
from Affymetrix (http://www.affymetrix.com/).
Identifying lncRNA associated with overall- and progression-free survival or cancer
subtype
We performed multivariate Cox proportional hazard (Cox regression) analysis to assess the
association between different covariates including lncRNA expression, ethnicity, age and
gender with overall or progression-free survival. In addition to lncRNA expression, we only
included the clinical outcome and covariate data that were available in individual dataset for
analysis. For GBM and Lung SCC, we included ethnicity, age and gender, whereas for
prostate cancer and OvCa, we only included ethnicity and age as additional covariates. The
Cox regression analyses were performed for overall survival in GBM and Lung SCC, for
progression-free survival in prostate cancer, and for both overall and progression-free
survival in OvCa. The molecular subtype information of 220, 487, 89 and 150 tumor
samples from GBM, OvCa, Lung SCC and prostate cancer were obtained from previous
studies18,19,31,32. One tailed Mann-Whitney U test was performed to compare the lncRNA
expression in each subtype with other subtypes in the same cancer. The lncRNA that showed
statistically higher expression (FDR < 0.05) in only one subtype were considered as
subtype-specific ones.
Identifying candidate driver lncRNA by integrating SCNA and expression data
The recurrent somatic copy number alteration (SCNA) regions of prostate cancer, GBM,
HGS-OvCa and Lung SCC were identified using GISTIC54,55 or RAE56 algorithm in
previous studies19,31,32. For prostate cancer, the SCNA regions were determined as the
union of SCNA regions from two different studies18,39. The magnitude of SCNAs was
estimated as log2 ratios of segmented copy number between cancer and control DNAs.
Among the lncRNA in the SCNA regions, we selected those that showed significant and
concordant expression change (one tailed Mann-whitney U test, p<0.05) in tumor samples
with corresponding somatic copy number gain (log2 ratio > 0.2) or loss (log2 ratio <-0.2), in
comparison with the other samples (Supplementary Table 2).
Coding potential analysis
To confirm that the two lncRNA PCAN-R1 and PCAN-R2 are non-coding, we used two
different methods, txCdsPredict from UCSC and phyloCSF57 to calculate their coding
potential. For coding potential calculation with phyloCSF, we used the multiple sequence
alignment of 29 mammalian genomes58. We chose the thresholds used previously
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(txCdsPredict = 80022 and phyloCSF = 1005), below which the transcripts were considered
non-coding. We found that the scores of all possible opening reading frames (ORFs) from
PCAN-R1 and PCAN-R2 transcripts were well below the thresholds (txCdsPredict score:
PCAN-R1, 470 and PCAN-R2, 359; phyloCSF score: PCAN-R1, -123.1434 and PCAN-R2,
-148.5448), supporting that these two lncRNA genes are non-coding.
Cell culture
LNCaP, CWR22Rv1 and PC3 cells were cultured in PRMI 1640 medium supplemented
with 10% fetal bovine serum (FBS). LNCaP-abl and LNCaP-AI cells were maintained in
phenol red-free RPMI 1640 medium with 10% charcoal/dextran-treated FBS. VCaP, Hela
and 293T cells were grown in DMEM with 10% FBS.
Quantitative RT-PCR (qRT-PCR) analysis
RNA was isolated using RNeasy Mini Kit (Qiagen). Reverse transcriptase (Invitrogen) was
employed for random-primed first-strand complementary DNA (cDNA) synthesis. Real-
time PCR was carried out on ABI Prism 7300 detection system using SYBR Green PCR
master mix. The ΔΔCt method was used to comparatively quantify the amount of mRNA
level. RPS28 gene expression served as the internal control. Primer sequences are listed
below: RPS28, 5′-CGATCCATCATCCGCAATG-3′(forward) and 5′-
AGCCAAGCTCAGCGCAAC-3′(reverse); PCAN-R1, 5′-
CAGGAACCCCCTCCTTACTC-3′(forward) and 5′-CTAGGGATGTGTCCGAAGGA-3′
(reverse); PCAN-R2, 5′-CTTGGCTGTGGTCACTCTGA-3′ (forward) and 5′-





GGGTCAAGCATGAAGAGGTC-3′ (forward) and 5′-
CAGAGGATGAGCCTTCTGAAA-3′ (reverse); ADAMTS17, 5′-
ACGACAACGTCCCGCTAAG-3′ (forward) and 5′-TCCTCCATACTCCTCGTTCTG-3′
(reverse);
RACE and northern blot analysis
5′ and 3′ rapid amplification of cDNA ends (RACE) were performed using the RLM-RACE
Kit (Ambion) following the manufacturer’s manual. Northern blot were performed using
DIG Northern Starter Kit (Roche). Digoxigenin (DIG) labeled RNA probes were generated
by in vitro transcription with T7 RNA polymerase from PCR products of corresponding
regions to detect specific lncRNA transcripts in poly(A) enriched mRNAs of LNCaP cells.
The PCR primers used to amplify specific regions for northern probes are listed below:
PCAN-R1, 5′-GACCTGGGCAACCCCAGCCTG-3′(sense) and 5′-
GATCACTAATACGACTCACTATAGGGCGCGAGGAGCGCCTCATCACC-3′
(antisense, including T7 promoter sequence); PCAN-R2, 5′-
GACAAATTCACCAAGAGCCTAG-3′(sense) and 5′-
GATCACTAATACGACTCACTATAGGGGAAGACTATGGGCTGCTTCCTT-3′
(antisense, including T7 promoter sequence).
RNA interference
The siRNA oligos were synthesized by Dharmacon, Inc. The target sequences are as
follows: siControl, 5′-GCGACCAACGCCTTGATTG-3′; siR1-1, 5′-
GGTGTCTCCATCCTCATTC-3′; siR1-2, 5′-CTCCCAGACCTCACGTCAA-3′; siR2-1,
5′-ACAGGAAGCTCTAGCAGTA-3′; siR2-2, 5′-CCATCAACAGTGAGAGGAA-3′.
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Cells were transfected with 20nM siRNA oligos by RNAiMax reagent (Invitrogen) in 24-
well plate. The knockdown efficiency was determined by qRT-PCR at 48-72 hours post
transfection.
Cell growth and soft agar assay
For cell growth assay, cells were plated in 24-well plates, transfected with indicated siRNA
oligos in triplicate and allowed to grow for another 5 days. Cells were counted every other
day by a hemocytometer. Anchorage-independent cell growth in soft agar was performed in
triplicate with 10,000 LNCaP cells per well suspended in 1.5 ml of medium containing
0.35% agar spread on top of 1.5 ml of 0.7% solidified agar in six-well plates. Colonies were
stained with crystal violet and counted after four weeks plating. Data were shown as Mean
+S.D. n=3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Human Exon array re-annotation and lncRNA classification
Affymetrix Human Exon array probe re-annotation pipeline for lncRNA was shown in (a).
(b) Adopting the classification scheme from a previous study (Ref. 20), lncRNA were
classified into four categories: intergenic, overlapping, intronic and exonic on the basis of
their relationship with protein-coding genes. (c) Pie charts showed the number of lncRNA in
each category for all collected lncRNA and for those with at least 4 uniquely mapped exon
array probes.
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Figure 2. The number and the expression profile of lncRNA that have disease-specific or
subtype-specific expression in prostate cancer, GBM, OvCa and Lung SCC
(a) The expression level of lncRNA that showed significantly differential expression
between cancer and normal prostate tissues were shown in heatmap across 29 normal
prostate samples, 131 primary and 19 metastatic prostate tumor samples. Several known
cancer-related lncRNA or lncRNA with established function in non-cancer context were
highlighted. (b) Venn diagram represented the number of subtype-specific lncRNA in three
cancers. The expression profile of top 100 lncRNA that exhibited significantly higher
expression in one subtype than the others for (c) GBM, (d) OvCa and (e) Lung SCC were
shown in heatmap (Note: the rank was based on the ascending order of the p-value). Tumor
samples were hierarchically clustered within each subtype.
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Figure 3. LncRNA associated with prognosis or in the genomic regions of SCNA
(a) Kaplan-Meier curve of two patient groups with higher (top 50%, n = 64) and lower
expression (bottom 50%, n = 64) of ENSG00000261582 in Lung SCC and OvCa (Red:
higher expression, blue: lower expression) was shown. The boxplot demonstrated that
ENSG00000261582 expressed higher in the “differentiated” subtype of OvCa than the other
subtypes. Both the p-value of multivariate Cox model for lncRNA expression and the p-
value of log-rank test were shown. (b) Kaplan-Meier curve for overall and progression-free
survival of two patient groups with higher (top 50%) and lower expression (bottom 50%) of
ENSG00000225128 in OvCa was shown. (c) The number of lncRNA located in the SCNA
(gain) and SCNA (loss) regions in different cancers was shown as Venn diagrams.
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Figure 4. The genetic alteration and the expression profile of PCAN-R1 and PCAN-R2 in normal
prostate tissues or prostate tumors and their transcript structure in cell line
(a) The heatmap showed the expression of PCAN-R1 and PCAN-R2 in normal prostate
tissue, primary and metastatic prostate cancer. (b) The boxplot of PCAN-R1 and PCAN-R2
expression in tumors with genomic amplification (n = 7 and n = 9) and in the tumors without
genomic amplification (n = 121 and n = 119) were compared. The boxplot showed the
expression distribution of PCAN-R1 and PCAN-R2 in two groups and mann-Whitney U test
was performed for the comparison. (c) The transcript structures of PCAN-R1 and PCAN-R2
from Ensembl annotation and determined by 5′ and 3′ RACE experiments in LNCaP cell
were shown. In addition, the H3K4me3, and DNase I hypersensitive region profile in the
same cell line were shown.
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Figure 5. Functional validation of PCAN-R1 and PCAN-R2
(a) The Northern blot of PCAN-R1 and PCAN-R2 transcripts was shown (Mr: RNA
marker). (b) The relative expression level of PCAN-R1 and PCAN-R2 upon knockdown by
two different siRNA (orange and green) and upon control siRNA treatment (purple) was
shown. (c) The growth curves of LNCaP cell with or without targeted siRNA-mediated
knockdown of PCAN-R1 or PCAN-R2 were shown. The growth curves of control siRNA-
treated cells and the growth curves of two targeted siRNA-treated cells were plotted in
purple, orange, and green, respectively. Data were shown as Mean+S.D. n=3. (d) The
number of soft-agar colony formation of LNCaP cell with or without targeted siRNA-
mediated knockdown of PCAN-R1 or PCAN-R2 was shown.
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Table 1
A summary table of literature-curated IncRNA
Ensembl ID Gene Name MW-U testp-value
Cancer vs
Normal Function annotation
ENSG00000225937 PCA3 9.50E-12 Up Prostate cancer
ENSG00000234741 GAS5 1.77E-06 Up Breast cancer
ENSG00000249859 PVT1 4.93E-11 Up Multiple cancers
ENSG00000226950 DANCR 3.03E-08 Up Development
ENSG00000253438 PCAT1 1.12E-05 Up Prostate cancer
ENSG00000227418 PCGEM1 4.49E-04 Up Prostate cancer
ENSG00000245532 NEAT1 0.00642 Up Nuclear speckle
ENSG00000258492 KCNQ1OT1 0.0103 Up Colon cancer
ENSG00000251164 HULC 0.0311 Up Multiple cancers
ENSG00000251562 MALAT1 0.285 - Multiple cancers
ENSG00000214548 MEG3 3.92E-08 Down Multiple cancers
ENSG00000238115 PRINS 1.37E-07 Down Autoimmune disease
ENSG00000243766 HOTTIP 1.95E-06 Down Development
ENSG00000235947 EGOT 2.48E-05 Down Development
ENSG00000214049 UCA1 2.11E-02 Down Bladder cancer
ENSG00000228630 HOTAIR 0.0573 - Multiple cancers
ENSG00000130600 H19 0.0842 - Multiple cancers
ENSG00000240498 ANRIL 0.699 - Prostate cancer
*
Known cancer-related IncRNA or IncRNA with established function in non-cancer context, and their regulation in cancer compared with normal
prostate tissue were listed. The statistical significance of their expression difference between cancer and normal prostate tissue was evaluated by
Mann–Whitney U test (MW-U test).
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